{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that geometric coefficient of variation could not be calculated for a single participant.","groupId":"OG002","spread":"NA","value":"51.50"},{"groupId":"OG003","spread":"31.76","value":"91.49"},{"groupId":"OG004","spread":"15.70","value":"260.62"},{"groupId":"OG005","spread":"38.51","value":"488.29"},{"groupId":"OG006","spread":"18.96","value":"1054.02"},{"groupId":"OG007","spread":"35.11","value":"1199.86"},{"groupId":"OG008","spread":"87.04","value":"2544.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG000","title":"Part 1: GSK2857916 0.03 mg/kg"},{"description":"Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG001","title":"Part 1: GSK2857916 0.06 mg/kg"},{"description":"Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG002","title":"Part 1: GSK2857916 0.12 mg/kg"},{"description":"Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG003","title":"Part 1: GSK2857916 0.24 mg/kg"},{"description":"Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG004","title":"Part 1: GSK2857916 0.48 mg/kg"},{"description":"Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG005","title":"Part 1: GSK2857916 0.96 mg/kg"},{"description":"Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG006","title":"Part 1: GSK2857916 1.92 mg/kg"},{"description":"Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG007","title":"Part 1: GSK2857916 3.40 mg/kg"},{"description":"Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG008","title":"Part 1: GSK2857916 4.60 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)","title":"Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1","type":"SECONDARY","unitOfMeasure":"Picograms per milliliter"}